Compare TPCS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | INTS |
|---|---|---|
| Founded | 1956 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 13.2M |
| IPO Year | 2008 | 2021 |
| Metric | TPCS | INTS |
|---|---|---|
| Price | $3.96 | $4.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 40.5K | 28.8K |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.20 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,031,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $2.88 | $0.19 |
| 52 Week High | $6.25 | $8.06 |
| Indicator | TPCS | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 33.18 |
| Support Level | $3.67 | $0.29 |
| Resistance Level | $4.71 | $8.06 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 24.20 | 18.92 |
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.